Laurus Labs Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Laurus Labs Ltd filed with BSE on 05 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Laurus Labs reported FY26 revenue of Rs 6,813 crore, up 23% year-on-year, driven by growth in the CDMO business and the Affordable Medicines (Generics) portfolio. EBITDA margin expanded by 6.7 percentage points to 26.8% for the year, with Q4 EBITDA margin at 28.9%, and profit after tax grew 148% to Rs 889 crore. Management outlined ongoing capex projects including Unit 7, peptide manufacturing, Animal Health capacity, Laurus Bio fermentation, and the KRKA joint venture formulation facility.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Total revenue: INR6,813 crores (FY26)
p. 4
“The company's revenues were INR6,813 crores with a growth of 23% over previous year.”
Satyanarayana Chava, page 4 of the filed PDF · View the filing
Gross margin: 60% range (FY26)
p. 4
“Gross margins were healthy and maintained around 60% range and EBITDA margins expanded by 6.7 percentage points to 26.8%.”
Satyanarayana Chava, page 4 of the filed PDF · View the filing
CDMO business revenue: INR2,080 crores (FY26)
p. 4
“The CDMO business delivered robust operational execution for the full year, clocking at a little over INR2,000 crores at INR2,080 crores.”
Krishna Chaitanya Chava, page 4 of the filed PDF · View the filing
Small molecule CDMO growth: 38%, INR1,896 crores (FY26)
p. 4
“For the small molecule CDMO, we have clocked a growth of about 38% with the sales for the full year at INR1,896 crores.”
Krishna Chaitanya Chava, page 4 of the filed PDF · View the filing
Small molecule CDMO Q4 sales: INR524 crores (Q4 FY26)
p. 4
“For the small molecule side in Q4, our sales stood at about INR524 crores.”
Krishna Chaitanya Chava, page 4 of the filed PDF · View the filing
Laurus Bio Q4 sales: INR65 crores (Q4 FY26)
p. 4
“Coming to Laurus Bio, the Bio division reported a Q4 sales of about INR65 crores.”
Krishna Chaitanya Chava, page 4 of the filed PDF · View the filing
Affordable Medicines Q4 revenue: INR1,223 crores (Q4 FY26)
p. 5
“Revenue from the Affordable Medicines division, formerly Generics, stood at INR1,223 crores in Q4 with the momentum sustained on an absolute basis, though the growth has been slightly moderated.”
Soumya Chava, page 5 of the filed PDF · View the filing
Affordable Medicines full year revenue: INR4,733 crores, 18% growth (FY26)
p. 5
“For the full year, the division delivered INR4,733 crores in revenue, reflecting a strong 18% growth.”
Soumya Chava, page 5 of the filed PDF · View the filing
R&D spend to sales: 4.1% (FY26)
p. 5
“On R&D front, our overall R&D spending to sales for FY '26 was at 4.1%, increased by 10% year-on-year, including our expenditure on cell and gene therapy space.”
Satyanarayana Chava, page 5 of the filed PDF · View the filing
Total income from operations Q4: INR1,812 crores (Q4 FY26)
p. 6
“For the quarter 4, we are at INR1,812 crores with a 5% growth.”
V. V. Ravi Kumar, page 6 of the filed PDF · View the filing
Gross margin Q4: 61.4% (Q4 FY26)
p. 6
“Gross margin maintained at a healthy level of 60.4% and for quarter 4, it is at 61.4%, mainly due to better product mix and some of the process improvement efforts.”
V. V. Ravi Kumar, page 6 of the filed PDF · View the filing
EBITDA: INR1,826 crores, 26.8% margin (FY26)
p. 6
“EBITDA for the year stands at INR1,826 crores with a 26.8% margin, which is well in line with our broader outlook.”
V. V. Ravi Kumar, page 6 of the filed PDF · View the filing
EBITDA Q4: INR523 crores, 28.9% margin (Q4 FY26)
p. 6
“For the quarter 4, EBITDA reported INR523 crores with a margin of 28.9% due to strong operating leverage.”
V. V. Ravi Kumar, page 6 of the filed PDF · View the filing
Profit after tax: INR889 crores, 148% growth (FY26)
p. 6
“Profit after tax for the year INR889 crores with a growth of 148% and quarter 4 is at INR279 crores.”
V. V. Ravi Kumar, page 6 of the filed PDF · View the filing
ROCE: 17.7% (FY26)
p. 6
“ROCE is around 17.7% improved from 9.7% for the previous year.”
V. V. Ravi Kumar, page 6 of the filed PDF · View the filing
Capex: INR1,070 crores full year, INR335 crores Q4 (FY26)
p. 6
“we invested close to INR335 crores for the quarter and INR1,070 crores for the full year.”
V. V. Ravi Kumar, page 6 of the filed PDF · View the filing
Net debt: INR2,285 crores (FY26)
p. 6
“Our net debt stood at INR2,285 crores and debt by EBITDA is 1.25 versus 2.3 last year on the back of strong internal cash flows.”
V. V. Ravi Kumar, page 6 of the filed PDF · View the filing
ARV revenue: INR2,800 crores (FY26)
p. 9
“We used to say INR2,500 crores plus or minus INR200 crores, but we did INR2,800 crores.”
Satyanarayana Chava, page 9 of the filed PDF · View the filing
Reactor volume: 8,200 cubic meters (FY26)
p. 3
“The company has exceeded 8,200 cubic meters of reactor volume for small molecule, API and intermediate manufacturing in FY '26.”
Satyanarayana Chava, page 3 of the filed PDF · View the filing
Cumulative DMF filings: 92
p. 5
“On the regulatory front, we have filed a cumulative 92 DMFs to date.”
Soumya Chava, page 5 of the filed PDF · View the filing
Oral solid formulation capacity: 12 billion units, 20% increase (FY26)
p. 5
“The oral solid facility expansion is progressing well with formulation capacity increased by 20% in FY '26 to 12 billion units.”
Soumya Chava, page 5 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Capex — around INR3,000 crores · next 2 years
stated firmly by Satyanarayana Chava
p. 14
“Although we said INR1,000 crores earlier, now depending on the prospects what we need capacity and what projects in front of us, we are increasing our capex spend there. And we expect to spend around INR3,000 crores in the next 2 years.”
Satyanarayana Chava, page 14 of the filed PDF · View the filing
Effective tax rate — 25% to 26% · FY27
stated firmly by V. V. Ravi Kumar
p. 14
“Effective tax rate will be around 25% to 26%. The standalone is definitely 25%. Then capex guidance is around INR3,000 crores in 2 years' time.”
V. V. Ravi Kumar, page 14 of the filed PDF · View the filing
Gross debt — FY27
stated conditionally by V. V. Ravi Kumar
p. 14
“Gross debt, It may slightly go up in the current year FY '27, but the debt by EBITDA may be maintain at the similar levels or may be softening from the current level.”
V. V. Ravi Kumar, page 14 of the filed PDF · View the filing
CDMO share of revenue — 50% · by 2030
stated firmly by Satyanarayana Chava
p. 16
“See we said the 2 things. One is we'll go to 50%. We also said by 2030.”
Satyanarayana Chava, page 16 of the filed PDF · View the filing
EBITDA margin — current level · FY27
stated firmly by Satyanarayana Chava
p. 10
“We are very confident on maintaining or improving this EBITDA margin in FY '27. We are comfortable in maintaining that. Yes.”
Satyanarayana Chava, page 10 of the filed PDF · View the filing
Gross margin
stated firmly by Satyanarayana Chava
p. 12
“See, we are very comfortable to say we'll maintain gross margin for sure despite our challenges on the solvent price and all. We are confident.”
Satyanarayana Chava, page 12 of the filed PDF · View the filing
CDMO growth — FY27
stated firmly by Satyanarayana Chava
p. 11
“If you compare year-to-year, we expect a good growth in CDMO segment. There could be lumpiness quarter-on-quarter. But we don't expect any challenges for us to record the growth in FY '27.”
Satyanarayana Chava, page 11 of the filed PDF · View the filing
Affordable Medicines growth — FY27
stated firmly by Soumya Chava
p. 15
“So for the next year also we have our order book pretty much in place. So we will continue to reflect a strong growth in the next year as well.”
Soumya Chava, page 15 of the filed PDF · View the filing
Laurus Bio Phase 1 fermentation capacity — end of 2026
stated firmly by Krishna Chaitanya Chava
p. 5
“Construction work for the commercial scale fermentation facility in Vizag is progressing well in line with the plan, and we expect the Phase 1 capacity to be operational by the end of 2026.”
Krishna Chaitanya Chava, page 5 of the filed PDF · View the filing
R&D spend to sales — similar percentage · FY27
stated firmly by Satyanarayana Chava
p. 5
“The spend is in line, and we expect a similar percentage going into the next year as well.”
Satyanarayana Chava, page 5 of the filed PDF · View the filing
Unit 7 greenfield project — March '27
stated firmly by Satyanarayana Chava
p. 3
“We are creating a large manufacturing greenfield project, Unit 7, and the first production will be ready for commercial validation by March '27 and four additional manufacturing during the next financial year FY '28 with a combined reactor volume of over 2,000 cubic meters.”
Satyanarayana Chava, page 3 of the filed PDF · View the filing
Peptide manufacturing block validation — Q2 FY27
stated firmly by Satyanarayana Chava
p. 3
“Second, commercial scale peptide manufacturing block will be ready for commercial scale validation during Q2 of this financial year FY '27.”
Satyanarayana Chava, page 3 of the filed PDF · View the filing
KRKA JV formulation facility Phase 1 — mid-2027
stated firmly by Satyanarayana Chava
p. 4
“Lastly, we are also spending on formulation facility under our KRKA joint venture in Hyderabad, and we expect Phase 1 will be completed by mid-2027.”
Satyanarayana Chava, page 4 of the filed PDF · View the filing
ARV percentage of revenue — FY27
stated firmly by Satyanarayana Chava
p. 16
“Quantum wise, we did INR2,800 crores ARV. That will remain constant. It will be around that number. But percentages, it will go down. It will go down.”
Satyanarayana Chava, page 16 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said initial batches are non-pharmaceutical industrial chemicals with less complex downstream processing, so contamination is the main challenge but they expect no downstream challenges.
Answered by Satyanarayana Chava
Asked by Sajal Kapoor: What is the biggest source of yield variability when scaling the Vizag 400 KL fermentation capacity?
p. 7
“See the biggest challenge in any fermentation is contamination and we don't have a very long tedious downstream processing for the products what we intend to manufacture in that facility.”
Satyanarayana Chava, page 7 of the filed PDF · View the filing
Management said the three recently commercialized APIs have long patent life with clear multi-year forecasts from partners and no destocking challenges expected.
Answered by Satyanarayana Chava
Asked by Bharath Siripurapu: Does Laurus have product concentration risk in CDMO given inventory destocking trends among peers?
p. 8
“In the last 18 months, we delivered 3 APIs for commercial. And those have patent life of several years.”
Satyanarayana Chava, page 8 of the filed PDF · View the filing
Management said gross margins remain similar between development and commercial phases but commercial phase generates higher EBITDA margin due to operating leverage.
Answered by Satyanarayana Chava
Asked by Chirag Shah: How does gross margin and EBITDA margin trajectory differ between CDMO development and commercial phases?
p. 9
“I would say whether it is development or commercial, in our opinion, gross margins will remain similar but we make more profit in commercial rather than development because development we employ more people during R&D, tech transfer and all.”
Satyanarayana Chava, page 9 of the filed PDF · View the filing
Management expressed confidence in maintaining or improving margins in FY27.
Answered by Satyanarayana Chava
Asked by Mehul Panjuani: How sustainable are the current 29% EBITDA margins?
p. 10
“We are very confident on maintaining or improving this EBITDA margin in FY '27. We are comfortable in maintaining that. Yes.”
Satyanarayana Chava, page 10 of the filed PDF · View the filing
Management noted some solvent price pressure in Q4 but said production has not been impacted and they see no near-term curtailment risk.
Answered by Satyanarayana Chava
Asked by Abhijith: Will raw material and geopolitical pressures impact operating costs going forward?
p. 11
“In quarter 4 of FY '26 some impact was there because of the solvent price increase. But I can tell you our production hasn't been impacted so far and we have enough visibility that in the next 3 months we don't have any challenges of curtailing operation because of higher prices of solvents or the availability of solvents.”
Satyanarayana Chava, page 11 of the filed PDF · View the filing
Management reiterated the 50% target with a 2030 timeframe.
Answered by Satyanarayana Chava
Asked by Foram Parekh: How soon can the 50% CDMO revenue contribution target be achieved?
p. 16
“See we said the 2 things. One is we'll go to 50%. We also said by 2030.”
Satyanarayana Chava, page 16 of the filed PDF · View the filing
Management explained they are scaling in a phased manner, citing time taken for prior capacity expansions and current revenue growth achieved.
Answered by Satyanarayana Chava
Asked by Venkat Vellipalli: Why hasn't fermentation capacity scaled to 2 million liters since the Richcore acquisition in 2021?
p. 14
“See, we thought we'll expand to 2 million, but we are doing in a phased manner. We have 250,000 liters right now.”
Satyanarayana Chava, page 14 of the filed PDF · View the filing
Management confirmed growth is expected but declined to give a percentage figure.
Answered by Soumya Chava
Asked by Vivek Agrawal: Can Affordable Medicines segment grow in double digits next year?
p. 15
“It's definitely growth, but we will not be able to comment on the percentage over here.”
Soumya Chava, page 15 of the filed PDF · View the filing
Risks flagged
Geopolitical disruptions may impact raw material availability and logistics, pressuring OTIF performance
p. 5
“However, increasing geopolitical disruptions may impact raw material availability and logistics, potentially creating a near-term pressure on OTIF performance across the industry.”
Soumya Chava, page 5 of the filed PDF · View the filing
Solvent price increases affecting input costs
p. 11
“In quarter 4 of FY '26 some impact was there because of the solvent price increase.”
Satyanarayana Chava, page 11 of the filed PDF · View the filing
Confidentiality constraints limit ability to comment on customer-specific developments
p. 14
“Any customer-related topics, we don't necessarily want to comment from our end. Unfortunately because of confidentiality terms, we are not able to comment.”
Krishna Chaitanya Chava, page 14 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.